Physician profile
Taylor Kell Ely
NPI 1467928770
$919.72
in general payments reported to CMS, 2019-2025
22 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $429 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.08 | 2024-2025 | |
| Novo Nordisk INC | $110.50 | 2024-2025 | Wegovy |
| Amgen INC. | $108.56 | 2024-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $62.54 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $60.23 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $56.36 | 2024-2025 | |
| Abbott Laboratories | $49.33 | 2025 | Freestyle Libre 3, Octrode |
| Otsuka America Pharmaceutical, INC. | $44.40 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $40.79 | 2024-2025 | Breztri |
| Edwards Lifesciences Corporation | $37.70 | 2025 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $30.94 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $23.37 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $23.34 | 2024 | Spravato |
| Astellas Pharma US INC | $22.06 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $21.22 | 2024 | Trintellix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.29 | 2024 | Zoryve |
| Lilly USA, LLC | $18.78 | 2024 | Mounjaro |
| Corcept Therapeutics | $17.99 | 2024 | Korlym |
| Nevro Corp. | $17.06 | 2024 | Senza |
| Inspire Medical Systems, INC. | $15.37 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.30 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $13.51 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.